Plasma NT1-tau and Aβ42 correlate with age and cognitive function in two large Down syndrome cohorts
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association..
INTRODUCTION: People with Down syndrome (DS) often develop Alzheimer's disease (AD). Here, we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment.
METHODS: Plasma NT1-tau, Aβ37 , Aβ40 , and Aβ42 levels were measured in a longitudinal discovery cohort (N = 85 participants, 220 samples) and a cross-sectional validation cohort (N = 239). We developed linear models and predicted values in the validation cohort.
RESULTS: Discovery cohort linear mixed models for NT1-tau, Aβ42 , and Aβ37:42 were significant for age; there was no main effect of time. In cross-sectional models, NT1-tau increased and Aβ42 decreased with age. NT1-tau predicted cognitive and functional scores. The discovery cohort linear model for NT1-tau predicted levels in the validation cohort.
DISCUSSION: NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia : the journal of the Alzheimer's Association - 19(2023), 12 vom: 01. Dez., Seite 5755-5764 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stern, Andrew M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aβ |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 18.02.2024 published: Print-Electronic UpdateOf: medRxiv. 2023 Mar 10;:. - PMID 36945447 Citation Status MEDLINE |
|---|
| doi: |
10.1002/alz.13382 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359396828 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359396828 | ||
| 003 | DE-627 | ||
| 005 | 20240218231845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alz.13382 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM359396828 | ||
| 035 | |a (NLM)37438872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stern, Andrew M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma NT1-tau and Aβ42 correlate with age and cognitive function in two large Down syndrome cohorts |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 18.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Mar 10;:. - PMID 36945447 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. | ||
| 520 | |a INTRODUCTION: People with Down syndrome (DS) often develop Alzheimer's disease (AD). Here, we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment | ||
| 520 | |a METHODS: Plasma NT1-tau, Aβ37 , Aβ40 , and Aβ42 levels were measured in a longitudinal discovery cohort (N = 85 participants, 220 samples) and a cross-sectional validation cohort (N = 239). We developed linear models and predicted values in the validation cohort | ||
| 520 | |a RESULTS: Discovery cohort linear mixed models for NT1-tau, Aβ42 , and Aβ37:42 were significant for age; there was no main effect of time. In cross-sectional models, NT1-tau increased and Aβ42 decreased with age. NT1-tau predicted cognitive and functional scores. The discovery cohort linear model for NT1-tau predicted levels in the validation cohort | ||
| 520 | |a DISCUSSION: NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer disease | |
| 650 | 4 | |a Aβ | |
| 650 | 4 | |a Down syndrome | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a plasma | |
| 650 | 4 | |a tau | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 700 | 1 | |a Van Pelt, Kathryn L |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Amirah K |e verfasserin |4 aut | |
| 700 | 1 | |a Ostaszewski, Beth |e verfasserin |4 aut | |
| 700 | 1 | |a Mapstone, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a O'Bryant, Sid |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Melissa E |e verfasserin |4 aut | |
| 700 | 1 | |a Christian, Bradley T |e verfasserin |4 aut | |
| 700 | 1 | |a Handen, Benjamin L |e verfasserin |4 aut | |
| 700 | 1 | |a Selkoe, Dennis J |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Frederick |e verfasserin |4 aut | |
| 700 | 1 | |a Head, Elizabeth |e verfasserin |4 aut | |
| 700 | 0 | |a Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia : the journal of the Alzheimer's Association |d 2005 |g 19(2023), 12 vom: 01. Dez., Seite 5755-5764 |w (DE-627)NLM168942356 |x 1552-5279 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:5755-5764 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alz.13382 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 12 |b 01 |c 12 |h 5755-5764 | ||